Logotype for AstraZeneca

AstraZeneca (AZN) investor relations material

AstraZeneca European Society of Cardiology Congress 2025 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for AstraZeneca
European Society of Cardiology Congress 2025 summary31 Aug, 2025

Strategic ambitions and growth outlook

  • Reaffirmed $80B/€80B total revenue ambition by 2030, driven by a diverse portfolio, new launches, and not dependent on future M&A.

  • Focus on expanding in cardiometabolic, oncology, and rare diseases, leveraging global reach and partnerships.

  • Emphasized innovative therapies targeting overlapping risk factors in cardiorenal and cardiometabolic diseases, including combination approaches and novel mechanisms.

  • Pipeline includes advanced modalities for weight management, risk factor modification, and multi-organ diseases.

  • Large patient populations remain uncontrolled or at risk despite current therapies, highlighting need for novel mechanisms.

Addressing unmet needs in cardiometabolic diseases

  • Cardiometabolic diseases are leading causes of death, with high prevalence of multi-morbidity in older adults.

  • Ambition to transform care by targeting dyslipidemia, hypertension, heart failure, kidney disease, and weight-related comorbidities.

  • Innovative combinations and new molecular entities are in development to address multi-risk factor diseases.

Bexarostat/Baxdrostat Phase III trial results and clinical insights

  • Bexarostat/Baxdrostat, a selective aldosterone synthase inhibitor, showed significant placebo-adjusted reductions in systolic BP (8.7 and 9.8 mmHg for 1mg and 2mg) in patients with uncontrolled or resistant hypertension.

  • Efficacy was consistent across all pre-specified subgroups, with robust 24-hour and nighttime BP control and sustained effects up to 32 weeks.

  • Reduced plasma aldosterone by 60–65% and demonstrated positive Phase II data for laroprostat (oral PCSK9 inhibitor) in dyslipidemia.

  • Safety profile was favorable, with low rates of significant hyperkalemia (1%), minimal discontinuations, and no adrenal insufficiency or relevant drug-drug interactions.

  • Ongoing Phase III trials in chronic kidney disease, heart failure prevention, and primary aldosteronism aim to expand indications.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next AstraZeneca earnings date

Logotype for AstraZeneca
Q3 2025
LIVE
6 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next AstraZeneca earnings date

Logotype for AstraZeneca
Q3 2025
LIVE
6 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Anglo-Swedish Pharmaceuticals

AstraZeneca is a multinational biopharmaceutical company established in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. Headquartered in Cambridge, UK, the firm operates globally, specializing in the research, development, manufacturing, and commercialization of prescription medications. It focuses on a range of therapeutic areas including oncology, cardiovascular, renal, metabolism, and respiratory diseases. AstraZeneca's products cater to a diverse set of medical needs and are distributed in numerous countries worldwide. The company is a major player in the global pharmaceutical industry, maintaining a strong commitment to scientific research and the development of new medicines.

A Successful Merger

As previously mentioned, AstraZeneca came to be following the merger of two established pharmaceutical companies. Astra AB, with roots dating back to 1913, had a notable history in pharmaceutical production, introducing various medicines to the market over the decades. Zeneca on the other hand traces its roots back to 1993 after separating from Imperial Chemical Industries. The British half of the modern-day company had a footprint in both therapeutic products and agrochemicals, although it eventually divested from the latter. The merger of these two entities aimed to consolidate resources, streamline research and development processes, and enhance their presence in the global pharmaceutical market. The combined company, now known as AstraZeneca, has since played a significant role in the industry, building upon the foundational knowledge and experience of the two merged parties.

Research and Development

AstraZeneca primarily focuses on the discovery, development, and commercialization of prescription medicines. Their core areas of activity encompass a range of medical conditions, including respiratory, cardiovascular, renal, metabolic, oncology, and autoimmune diseases. The company also engages in significant research and development efforts, with research centers in the UK, Sweden, and the USA. This focus AstraZeneca was one of the pharmaceutical companies heavily involved with the global effort of finding a suitable vaccine during the Covid-19 pandemic. This is an effort they succeeded in, and together with companies like Pfizer and Moderna, they were a key player in the global vaccination effort.

Serving Patients Worldwide

As is common with large pharmaceutical companies, AstraZeneca has a presence in all corners of the world and the company operates in over 100 countries. It has manufacturing and commercial operations distributed across major markets including North America, Europe, Asia, and emerging economies.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage